Back to Search
Start Over
Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis
- Source :
- European Journal of Dermatology. 30:699-709
- Publication Year :
- 2020
- Publisher :
- John Libbey Eurotext, 2020.
-
Abstract
- The survival of patients with melanoma of unknown primary (MUP) is proposed to be more favourable than that for melanoma of known primary (MKP). This may be due to an enhanced initial immune response in patients with MUP, which could also affect the efficacy of immunotherapy in advanced disease. The present study compared therapeutic outcome and survival in Stage III and IV MUP and MKP. Medical records of 67 MUP and 536 MKP patients were reviewed. Median overall survival (OS) in Stage III patients was 77 months versus 54 months in patients with MUP and MKP, respectively (p = 0.11). Median OS was prolonged in MUP patients receiving adjuvant first-line ipilimumab (p = 0.14). In contrast, OS tended to be more favourable in patients with MKP after palliative first-line ipilimumab treatment (p = 0.16). Yet, no statistically significant differences in OS were detected between the groups. Moreover, survival after anti-PD-1-antibody treatment was similar in patients with MUP and MKP. Overall, we observed similar survival outcomes after immunotherapy in patients with MUP and MKP. These findings provide no evidence of difference in responsiveness to immunotherapy between patients with MUP and MKP.
- Subjects :
- Adult
Male
0301 basic medicine
Oncology
medicine.medical_specialty
Skin Neoplasms
medicine.medical_treatment
Ipilimumab
Dermatology
Young Adult
03 medical and health sciences
Antineoplastic Agents, Immunological
0302 clinical medicine
Immune system
Internal medicine
medicine
Humans
In patient
Stage (cooking)
Melanoma
Aged
Neoplasm Staging
Retrospective Studies
Aged, 80 and over
business.industry
Immunotherapy
Middle Aged
medicine.disease
Survival Rate
Treatment Outcome
030104 developmental biology
030220 oncology & carcinogenesis
Unknown primary
Neoplasms, Unknown Primary
Female
business
Adjuvant
medicine.drug
Subjects
Details
- ISSN :
- 19524013 and 11671122
- Volume :
- 30
- Database :
- OpenAIRE
- Journal :
- European Journal of Dermatology
- Accession number :
- edsair.doi.dedup.....4cf72f68cd59894f072b32c8a2a21c44